<DOC>
	<DOCNO>NCT00641030</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , clofarabine melphalan , donor stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient , may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I trial study side effect best dose clofarabine give together high-dose melphalan follow donor stem cell transplant treat patient acute myeloid leukemia , acute lymphocytic leukemia , myelodysplastic syndrome .</brief_summary>
	<brief_title>Clofarabine High-Dose Melphalan Followed Donor Stem Cell Transplant Patients With Acute Myeloid Leukemia , Acute Lymphocytic Leukemia , Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose toxicity clofarabine administer high-dose melphalan condition regimen patient undergo allogeneic stem cell transplantation acute myeloid leukemia , acute lymphocytic leukemia , myelodysplastic syndrome . - To assess efficacy regimen facilitate engraftment patient . - To perform correlative laboratory study engraftment , immune reconstitution , therapeutic outcome . OUTLINE : This dose-escalation study clofarabine . Patients stratify accord age ( &lt; 18 year vs ≥ 18 year ) . - Reduced-intensity conditioning regimen : Patients receive clofarabine IV 30 minute day -9 -5 high-dose melphalan IV 30 minute day -4 . Cohorts 3-6 patient receive escalate dos clofarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . - Allogeneic stem cell transplantation : Patients undergo allogeneic stem cell transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 10 hour orally twice daily begin day -1 continue day 90-100 , follow taper absence GVHD . Patients also receive mycophenolate mofetil IV orally twice daily begin day 0 continue day 28 , follow taper absence GVHD . Patients undergo blood and/or bone marrow sample collection periodically correlative laboratory study . Samples examine marker immune reconstitution ( i.e. , CD8+ T lymphocytes , CD4+ T lymphocytes , NK cell , B cell , monocyte ) flow cytometry diversity reconstitute T-cell repertoire PCR-based T-cell receptor repertoire analysis . Samples also examine gene expression hRRM2 marker apoptosis ( i.e. , Bcl-2 , Bid , NFkB2 , Bcl-3 ) real-time RT-PCR marker ribonucleotide reductase inhibition ( i.e. , dCTP level circulate peripheral blood mononuclear cell ) . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Acute myeloid leukemia Acute lymphocytic leukemia Myelodysplastic syndrome Disease meet 1 follow criterion : In first complete remission ( CR ) In second CR In relapse No 50 % blast bone marrow Not deem eligible standard transplantation regimen attend physician , high risk relapse No suspect proven CNS leukemia HLAmatched ( 6/6 ) sibling donor available PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % Glomerular filtration rate ( pediatric patient ) creatinine clearance ≥ 60 mL/min OR serum creatinine &lt; 1.5 time upper limit normal ( ULN ) Serum bilirubin ≤ 2.0 mg/dL AST ALT ≤ 2.5 time ULN LVEF ≥ 50 % ECHO MUGA scan DLCO FEV_1 ≥ 40 % predict Not pregnant Negative pregnancy test No concurrent uncontrolled illness include , limited , follow : Ongoing , active , poorly control infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Poorly control pulmonary disease Psychiatric illness/social situation would limit compliance study requirement No active cytomegalovirus ( CMV ) fungal disease HIV negative PRIOR CONCURRENT THERAPY : Recovered prior intensive chemotherapy ( pediatric patient ) At least 100 day since prior autologous stem cell transplantation At least 100 day since prior radiotherapy administer part transplantation condition regimen At least 4 week since prior chemotherapy At least 24 hour since prior hydroxyurea blast count control</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
</DOC>